Galapagos achieved the second milestone under the antibody collaboration with Novartis for bone-related diseases, triggering a payment of $1 million to Galapagos. Galapagos will pay $750,000 of this amount to ProStrakan as part of their December 2006 agreement. The Novartis/ProSkelia SASU (formerly a subsidiary of ProStrakan) collaboration was formed in September 2006. Under the terms of the original agreement with Novartis, total milestones could exceed $100 million plus royalties. The fir...